Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of ($0.29), versus ($0.36) reported last year. Revenue for the quarter came in at $4.4 million, versus $3.5 million reported last year.

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.